PS1029 CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Journal article

Open access

Peer reviewed

M. Heuser, W. Fiedler, M.A. Sekeres, P. Montesinos, B. Leber, A. Merchant, C. Papayannidis, J.A. Pérez-Simón, C.J. Hoang, W.W. Ma, …

HemaSphere, Vol.3(S1), pp.464-465

2019-06

Files and links (1)

url

https://doi.org/10.1097/01.hs9.0000562412.43628.dfView

Published (Version of record) Open

1 Record Views

Title: PS1029 CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL
Creators: M. Heuser
W. Fiedler
M.A. Sekeres
P. Montesinos
B. Leber
A. Merchant
C. Papayannidis
J.A. Pérez-Simón
C.J. Hoang
W.W. Ma
M. Zeremski
A. O’Connell
G. Chan
J.E. Cortes
Publication Details: HemaSphere, Vol.3(S1), pp.464-465
Academic Unit: UMMG Dept of Medicine - Hematology/Oncology; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031757381202976